Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 133-144 , February 2009

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression

References 

  1. Mechoulam R, Devane WA, Breuer A, et al. A random walk through a cannabis field. Pharmacology Biochemistry and Behavior. 1991;40:461–464
  2. Zuardi AW. History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria. 2006;28:153–157
  3. Piomelli D. The molecular logic of endocannabinoid signalling. Nature reviews. Neuroscience. 2003;4:873–884
  4. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58:389–462
  5. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handbook of Experimental Pharmacology. 2005;168:299–325
  6. Di Marzo V. Endocannabinoids: synthesis and degradation. Reviews of Physiology Biochemistry and Pharmacology. 2008;160:1–24
  7. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. Journal of Endocrinological Investigation. 2006;29:27–46
  8. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352:1611–1616
  9. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist. 2007;13:422–432
  10. McGregor IS, Arnold JC, Weber MF, et al. A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Research. 1998;802:19–26
  11. Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. The Journal of Neuroscience. 2007;27:11700–11711
  12. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology. 2007;52:958–965
  13. Rubino T, Guidali C, Vigano D, et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology. 2008;54:151–160
  14. Rubino T, Realini N, Castiglioni C, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cerebral Cortex. 2008;18:1292–1301
  15. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572
  16. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior. 2005;81:331–342
  17. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530–534
  18. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. The Journal of Pharmacology and Experimental Therapeutics. 2006;318:304–311
  19. Steiner MA, Wanisch K, Monory K, et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. The Pharmacogenomics Journal. 2008;8:196–208
  20. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addiction Biology. 2008;13:196–212
  21. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience. 1999;11:4213–4225
  22. Katona I, Sperlágh B, Sík A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. The Journal of Neuroscience. 1999;19:4544–4558
  23. Monory K, Massa F, Egertova M, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51:455–466
  24. Oropeza VC, Mackie K, Van Bockstaele EJ. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Research. 2007;1127:36–44
  25. Harkany T, Dobszay MB, Cayetanot F, et al. Redistribution of CB1 cannabinoid receptors during evolution of cholinergic basal forebrain territories and their cortical projection areas: a comparison between the gray mouse lemur (Microcebus murinus, primates) and rat. Neuroscience. 2005;135:595–609
  26. Häring M, Marsicano G, Lutz B, et al. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience. 2007;146:1212–1219
  27. Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. The AAPS Journal. 2006;8:E693–E708
  28. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. British Journal of Pharmacology. 2007;152:624–632
  29. Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nature Neuroscience. 2007;10:870–879
  30. Parker LA, Kwiatkowska M, Mechoulam R. Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiology & Behavior. 2006;87:66–71
  31. Rock EM, Limebeer CL, Mechoulam R, et al. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl). 2008;196:389–395
  32. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews. 2006;27:73–100
  33. Martin BR, Compton DR, Little PJ, et al. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. NIDA Research Monograph. 1987;79:108–122
  34. Monory K, Blaudzun H, Massa F, et al. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biology. 2007;5:e269
  35. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl). 2002;163:111–117
  36. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. European Neuropsychopharmacology. 2005;15:593–599
  37. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. The Journal of Clinical Investigation. 2005;115:3104–3116
  38. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. The Journal of Pharmacology and Experimental Therapeutics. 1990;253:1002–1009
  39. Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000;147:436–438
  40. Micale V, Cristino L, Tamburella A, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 25 June 2008. doi:10.1038/npp.2008.98.
  41. Haller J, Bakos N, Szirmay M, et al. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. European Journal of Neuroscience. 2002;16:1395–1398
  42. Martin M, Ledent C, Parmentier M, et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159:379–387
  43. Marsch R, Foeller E, Rammes G, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. The Journal of Neuroscience. 2007;27:832–839
  44. Moreira FA, Kaiser N, Monory K, et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008;54:141–150
  45. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Natural Medicines. 2003;9:76–81
  46. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:18620–18625
  47. Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biological Psychiatry. 2007;62:1103–1110
  48. Hill MN, Gorzalka BB. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. European Journal of Pharmacology. 2004;499:291–295
  49. Vann RE, Gamage TF, Warner JA, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug and Alcohol Dependence. 2008;94:191–198
  50. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008;153:199–215
  51. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol–recent advances. Chemistry & Biodiversity. 2007;4:1678–1692
  52. Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 2004;44:461–467
  53. Murray RM, Morrison PD, Henquet C, et al. cannabis, the mind and society: the hash realities. Nature Reviews. Neuroscience. 2007;8:885–895
  54. Seamon MJ, Fass JA, Maniscalco-Feichtl M, et al. Medical marijuana and the developing role of the pharmacist. American Journal of Health-System Pharmacy. 2007;64:1037–1044
  55. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2004;28:849–863
  56. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Medicine. 2006;7:25–29
  57. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet. 1995;345:579
  58. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. The Journal of Pain. 2008;9:164–173
  59. Phan KL, Angstadt M, Golden J, et al. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. The Journal of Neuroscience. 2008;28:2313–2319
  60. Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002;164:407–415
  61. Huestis MA. Human cannabinoid pharmacokinetics. Chemistry & Biodiversity. 2007;4:1770–1804
  62. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research. 2006;39:421–429
  63. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517–1526
  64. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299–306
  65. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210–220
  66. Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. European Journal of Neurology. 2007;14:290–296
  67. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple sclerosis. 2006;12:639–645
  68. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94:1311–1322
  69. Agrawal A, Pergadia ML, Lynskey MT. Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions?. The American Journal on Addictions. 2008;17:199–208
  70. Chung T, Martin CS, Cornelius JR, et al. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction. 2008;103:787–799
  71. Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51:1356–1367
  72. Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addiction Biology. 2008;13:239–252
  73. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews. 2002;54:161–202
  74. Navarro M, Hernandez E, Munoz RM, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997;8:491–496
  75. Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behavioural Pharmacology. 2005;16:405–413
  76. Kamprath K, Marsicano G, Tang J, et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. The Journal of Neuroscience. 2006;26:6677–6686
  77. Patel S, Hillard CJ. Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. European Journal of Neuroscience. 2008;27:2821–2829
  78. Cota D, Steiner MA, Marsicano G, et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2007;148:1574–1581
  79. Patel S, Roelke CT, Rademacher DJ, et al. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 2004;145:5431–5438
  80. Patel S, Roelke CT, Rademacher DJ, et al. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. European Journal of Neuroscience. 2005;21:1057–1069
  81. Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB Journal. 2005;19:1704–1706
  82. Aso E, Ozaita A, Valdizan EM, et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. Journal of Neurochemistry. 2008;105:565–572
  83. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behavioural Pharmacology. 2005;16:333–352
  84. Steiner MA, Marsicano G, Nestler EJ, et al. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology. 2008;33:54–67
  85. Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behavioural Pharmacology. 2003;14:573–582
  86. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry. 2005;57:261–267
  87. Tzavara ET, Davis RJ, Perry KW, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology. 2003;138:544–553
  88. Witkin JM, Tzavara ET, Davis RJ, et al. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences. 2005;26:609–617
  89. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry. 2001;58:322–328
  90. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  91. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine. 2005;353:2121–2134
  92. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2006;295:761–775
  93. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–1672
  94. Van Gaal LF, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31(Suppl. 2):S229–S240
  95. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–1713
  96. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA: The Journal of the American Medical Association. 2008;299:1547–1560
  97. Addy C, Li S, Agrawal N, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. Journal of Clinical Pharmacology. 2008;48:418–427
  98. Addy C, Rothenberg P, Li S, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. Journal of Clinical Pharmacology. 2008;48:734–744
  99. Addy C, Wright H, Van LK, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism. 2008;7:68–78
  100. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Archives of Internal Medicine. 2003;163:2058–2065

PII: S1521-690X(08)00101-2

doi: 10.1016/j.beem.2008.09.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 133-144 , February 2009

Article Tools